Gordon Gochenauer

Articles by Gordon Gochenauer

Advances in Metastatic Melanoma Bring Price Competition, Redefinition of Value, and Likely Increased Payer Utilization Management

October 14th 2013

Traditionally, payers have been increasingly more proactive in their management of drug expenditures in cancers with the highest prevalence and with the more costly therapeutics.

Latest Updated Articles

Advances in Metastatic Melanoma Bring Price Competition, Redefinition of Value, and Likely Increased Payer Utilization Management
October 14th 2013

Trending on OncLive

In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas

Pumitamig Plus Chemo Demonstrates Encouraging Efficacy in Frontline NSCLC

Experts Weigh In on Some of the Most Impactful Data in Melanoma From ASCO 2026

Emiltatug Ledadotin Elicits Responses in Aggressive Adenoid Cystic Carcinoma

A global, randomized, double-blinded, Phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an IDH1/2 mutation (INDIGO): updated efficacy and safety